| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| Other Sizes |
| Targets |
The specific biological target of 5-Sulfosalicylic acid is not clearly defined. Its anticancer activity against breast cancer cell lines suggests it may interact with cellular pathways involved in proliferation or survival. Its antioxidant activity indicates it can scavenge reactive oxygen species. As an organocatalyst, it targets various substrates in chemical reactions. Its mechanism of action in biological systems is not fully elucidated.
|
|---|---|
| ln Vitro |
5-Sulfosalicylic acid (0.5-4 mM, 24 hours) decreases MCF-7 cell viability [1].
In vitro, 5-Sulfosalicylic acid is effective against breast cancer cell lines. It has also been shown to have antioxidant activities. Specific IC₅₀ values or detailed cytotoxicity data against specific cell lines are not provided in the available sources. Its activity is attributed to its sulfonated salicylic acid structure. |
| ln Vivo |
Specific in vivo activity data for 5-Sulfosalicylic acid are not provided in the available sources. While the compound exhibits in vitro activity against breast cancer cell lines, no in vivo studies in animal models are described. Its antioxidant properties suggest potential in vivo benefits, but specific data are lacking.
|
| Enzyme Assay |
A cell-free assay for 5-Sulfosalicylic acid is not applicable as it is not primarily an enzyme inhibitor or receptor ligand. Its antioxidant activity can be measured in cell-free systems using assays such as DPPH or ABTS radical scavenging assays. Its role as an organocatalyst can be assessed in chemical reactions. Its use in electrochemical immunoassays involves its incorporation into a polymer matrix for biosensor applications.
|
| Cell Assay |
Cytotoxicity assay [1]
Cell Types: MCF-7 and HUVEC Cell Tested Concentrations: 0.5, 1, 2, 4 mM Incubation Duration: 24 hrs (hours) Experimental Results: The viability of MCF-7 and HUVEC control cells were 63.3% and 70.4% respectively at 1 mM 5-Sulfosalicylic acid. Cellular assays for 5-Sulfosalicylic acid typically involve assessing its cytotoxic effects on cancer cell lines, such as breast cancer cells. Cells are treated with varying concentrations of the compound, and cell viability is measured using standard assays (e.g., MTT). Its antioxidant activity can also be evaluated in cells by measuring its ability to reduce oxidative stress markers. Specific protocols are not detailed in the available sources. |
| Animal Protocol |
In vivo animal experiments for 5-Sulfosalicylic acid are not described in the available sources. As a compound with in vitro anticancer and antioxidant activity, it could potentially be evaluated in animal models of cancer or oxidative stress. However, no such data or protocols are provided.
|
| ADME/Pharmacokinetics |
Pharmacokinetic (PK) properties of 5-Sulfosalicylic acid are not reported in the available sources. As a small molecule, its absorption, distribution, metabolism, and excretion (ADME) profiles have not been characterized. The compound is a solid at room temperature. Standard storage conditions for research compounds apply.
|
| Toxicity/Toxicokinetics |
Toxicity data for 5-Sulfosalicylic acid indicate that it is less toxic compared to other compounds. However, specific toxicological information, such as LD₅₀ values, is not provided. As with all research compounds, it is intended for research use only and not for human consumption. Standard laboratory safety precautions should be observed when handling this compound.
|
| References |
|
| Additional Infomation |
5-Sulfosalicylic acid is an aromatic sulfonic acid, a compound in which benzoic acid is substituted at the C-2 position with a hydroxyl group and at the C-5 position with a sulfonic acid group. It is a metabolite. It belongs to the aromatic sulfonic acid class and is a member of the benzoic acid and phenolic compounds. Functionally, it is related to benzoic acid and phenolic compounds. 2-Hydroxy-5-sulfobenzoic acid has been reported in bovine (Bos taurus), and relevant data are available.
5-Sulfosalicylic acid (CAS: 97-05-2) is a sulfonated salicylic acid derivative with reported anticancer and antioxidant activities. It is also known as 2-hydroxy-5-sulfobenzoic acid. The compound is used in electrochemical immunoassays for detecting the gastric cancer biomarker CA72-4 and as an organocatalyst. It is effective against breast cancer cell lines and is considered less toxic. It is not an approved drug and is primarily used as a research chemical and laboratory reagent. |
| Molecular Formula |
C7H6O6S
|
|---|---|
| Molecular Weight |
218.1839
|
| Exact Mass |
217.988
|
| CAS # |
97-05-2
|
| Related CAS # |
1837-99-6 (berrylium[1:1] salt);831-54-9 (mono-hydrochloride salt)
|
| PubChem CID |
7322
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.8±0.1 g/cm3
|
| Melting Point |
120°C
|
| Index of Refraction |
1.650
|
| LogP |
-0.69
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
14
|
| Complexity |
316
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(C1C(O)=CC=C(S(O)(=O)=O)C=1)O
|
| InChi Key |
YCPXWRQRBFJBPZ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C7H6O6S/c8-6-2-1-4(14(11,12)13)3-5(6)7(9)10/h1-3,8H,(H,9,10)(H,11,12,13)
|
| Chemical Name |
2-hydroxy-5-sulfobenzoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~1145.84 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (9.53 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (9.53 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (9.53 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.5834 mL | 22.9169 mL | 45.8337 mL | |
| 5 mM | 0.9167 mL | 4.5834 mL | 9.1667 mL | |
| 10 mM | 0.4583 mL | 2.2917 mL | 4.5834 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
